Dr. van den Brink Highlights Four Abstracts From ASH 2015

Marcel R.M. van den Brink, MD, PhD, Head, Division of Hematologic Oncology, Memorial Sloan Kettering Cancer Center, provides an overview of four notable studies being presented at the 2014 American Society of Hematology (ASH) Meeting and Exposition. Van den Brink highlights the following studies:

Therapeutic Targeting of Spliceosomal Mutant Myeloid Leukemias through Modulation of Splicing Catalysis

Stanley Chun-Wei Lee, PhD

Implications of Minimal Residual Disease Negative Complete Remission (MRD-CR) and Allogeneic Stem Cell Transplant on Safety and Clinical Outcome of CD19-Targeted 19-28z CAR Modified T Cells in Adult Patients with Relapsed, Refractory B-Cell ALL

Jae H. Park, MD

Safety and Efficacy of AG-221, a Potent Inhibitor of Mutant IDH2 That Promotes Differentiation of Myeloid Cells in Patients with Advanced Hematologic Malignancies: Results of a Phase I/II Trial

Eytan M. Stein, MD

The Abundance of Certain Bacteria in the Intestinal Flora Is Associated with Relapse after Allogeneic Hematopoietic Stem Cell Transplantation

Jonathan Peled, MD, PhD